Myeloma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• The patient (or their guardian, for younger patients) has read the study information, agrees to take part, and has signed a consent form
• The patient is older than 3 years of age (any gender)
• The patient has a confirmed diagnosis of one of the following: certain types of B-cell lymphoma (including diffuse large B-cell lymphoma and several related subtypes), acute B-cell leukemia that has come back or did not respond well to prior chemotherapy, or multiple myeloma that has returned or stopped responding to treatment
• For patients with B-cell lymphoma, at least one measurable area of disease must be visible on imaging scans at the start of the study
• For patients with acute B-cell leukemia, a certain minimum level of abnormal cells must be detected in the bone marrow at screening
• Tumour cells must show a specific protein marker called CD19, confirmed by laboratory testing
• The patient's liver, kidneys, heart, and lungs must be functioning at an acceptable level, as measured by specific blood and heart tests (confirm with trial site for exact values)
• The patient must have a physical functioning score (called an ECOG score) of 0, 1, or 2 — meaning they are able to carry out at least some daily activities
• The treating doctor expects the patient to survive for more than 3 months
• Patients who could become pregnant agree to use reliable contraception from the time of signing the consent form until 2 years after receiving the study treatment

Who may not be able to join:

• People who have had a significant brain or nervous system condition in the 6 months before screening, such as a stroke, epilepsy, dementia, Parkinson's disease, or a serious mental health disorder
• Patients with acute B-cell leukemia whose disease has returned only outside the bone marrow (isolated extramedullary relapse)
• People who have another active cancer in addition to the qualifying blood cancer diagnosis
• People who received certain anti-cancer treatments (such as chemotherapy, targeted drug therapy, or radiation) within a specific period before cell collection (confirm exact timeframes with trial site)
• People who received a vaccination or B-cell targeted therapy within 4 weeks before screening
• People who have a systemic autoimmune disease or a condition that affects the immune system
• People who have experienced a significant immune reaction related to a prior transplant (called graft-versus-host disease, grades 2–4) within the 4 weeks before screening
• People with serious heart conditions such as angina, heart attack, heart failure, or significant irregular heartbeat
• People with a known history of severe allergic reactions to any of the drugs used in this study, including cyclophosphamide, fludarabine, or DMSO
• People with active hepatitis B, hepatitis C, HIV, or syphilis infections
• People with an active infection that requires intravenous antibiotics or hospital admission
• Women who are pregnant or currently breastfeeding
• People whom the investigating doctor considers unsuitable for the study for safety, effectiveness, or other reasons

Important: Always verify eligibility with the trial site directly before applying.